#cobenfy

[schizosupport]

Speaking of drugs, there's a new antipsychotic that has now been approved by the FDA, 'Cobenfy'. What's interesting about it is that its mechanism of action is completely different from any other existing antipsychotic since the 1950s where the 'current lineup' was born. It regulates acetylcholine (related to memory, learning and attention) and doesn't touch the dopaminergic system at all. In clinical trials it has proven an effective treatment for positive symptoms of psychosis at least on par with existing antipsychotics. A completely new mechanism of action gives hope to people who are treatment resistant and that's likely where it will be used most at first. But it is also going to have a very very different side effect profile, so for a lot of people this could prove more tolerable and helpful than the existing medications.

Now that it's going to start being prescribed, it will generate a lot of real world data. I'm daring to be cautiously optimistic.

[mindblowingscience]

Experts expressed enthusiasm Friday after US health regulators approved the first new form of treatment for schizophrenia in decades. The drug, called Cobenfy and developed by US pharma giant Bristol Myers Squibb, works differently from existing treatments, targeting the so-called cholinergic receptors, not the dopamine receptors. "This drug takes the first new approach to schizophrenia treatment in decades," Tiffany Farchione, a top official in the US Food and Drug Administration (FDA), said in a statement Thursday.

Continue Reading.

[dorianbrightmusic]

New Antipsychotic FDA Approval – Cobenfy

Cobenfy (xanomeline/trospium chloride) has just been approved for schizophrenia treatment in the US. This is huge. It's the first antipsychotic in decades to not target dopamine directly. It's got a much, much better side-effect profile, and it might work for negative and cognitive symptoms.

FOR MORE READING – news report/patient-centred plain language overview: See here.

FOR MORE READING – scientific evidence report: See here (note: the drug is referred to as 'KarXT' in this report).

I couldn't be happier right now. People with psychosis go through so, so much trying to find medications that are both useful and tolerable, and psychiatry has historically neglected psychotic people's needs so, so awfully. (Not to mention how little there is that actually helps with anything other than positive symptoms.) So I'm really, really hoping that with the proof that we can, in fact, make antipsychotics that aren't based on the same old pharmacological things we've tried before. Cobenfy is a muscarinic agonist/antagonist in fixed combination – and it also indirectly regulates dopamine and glutamate. And given that we know both dopamine and NMDA are probably involved in schizophrenia somehow – AND that treating things to do with either is hard – this is so, so, so exciting.

This isn't to say Cobenfy doesn't have side-effects (the most common ones being nausea, constipation, dyspepsia, vomiting, hypertension, dry mouth, and tachycardia. We also know that there is a small risk of extrapyramidal symptoms, and that prolactin-related side-effects do happen, unfortunately). We don't know much about how it affects folks in the long-term, or much about the long-term tardive dyskinesia risk. But even so, it's progress compared to some of the worse antipsychotic side-effects.

Moreover, there is a possibility it might be useful for negative and cognitive symptoms. Holy crap.

I'm really really really excited. I hope this is the start of a shift in psychiatry towards better standards of patient-centred care for psychosis. Y'all have deserved better for far too long – here's hoping this is the start of more ethical, effective treatment.

[malazansapper]

Anyone with schizophrenia switched to the new drug cobenfy?

[graphicabhi]

Navigating the Loss of Exclusivity: Big Pharma’s Updated Strategy

Facing the Patent Cliff Again: Can the Biopharmaceutical Sector Keep Pace with Innovation?

The biopharmaceutical sector is once again encountering a significant wave of loss of exclusivity (LOE), reminiscent of the "patent cliff" that shook the industry in the early 2010s. Key medications like Tagrisso (tagrisso patent expiration), Calquence (calquence patent expiry), and Olaparib (olaparib patent expiration) are nearing their patent expiration dates, compelling major pharmaceutical companies to respond swiftly. The issue of drug loss of exclusivity is not limited to the United States—it also impacts emerging markets such as India and Japan (india loss of exclusivity analysis, japan loss of exclusivity analysis). In response, companies are crafting more sophisticated loss of exclusivity strategies to protect product value and retain a competitive edge.

Understand how to prepare for the end of market exclusivity and protect your brand – read the full guide here: https://www.delveinsight.com/blog/navigating-the-loss-of-exclusivity?utm_source=blog&utm_medium=promotion&utm_campaign=akpr 

Merck: Strengthening Through Pipeline Innovation

With the blockbuster drug Keytruda set to face generic competition—raising the question: when does Keytruda lose exclusivity?—Merck is tackling the loss of exclusivity head-on. The company is investing heavily in its pipeline, particularly in the oncology and immunology spaces. Its introduction of Cobenfy, along with advancements in next-generation checkpoint inhibitors and vaccines, underscores a strong, pipeline-driven medical strategy to mitigate loss of exclusivity and enhance long-term portfolio resilience.

AstraZeneca: Science-Led Diversification to Offset Risk

As AstraZeneca prepares for the LOE of drugs like Calquence and Tagrisso, the company is leaning into science-backed diversification. This includes robust R&D initiatives and strategic partnerships. With promising assets like Enhertu, including a subcutaneous formulation on the horizon, AstraZeneca’s loss of exclusivity pharma strategy is anchored in scientific progress. Mergers, acquisitions, and a deepening pipeline are helping to buffer the effects of pharma loss of exclusivity, while paving the way for future treatments.

Bristol Myers Squibb: Balancing Growth and Cost Ahead of Patent ExpiryWith Pomalyst loss of exclusivity on the near-term horizon, Bristol Myers Squibb (BMS) is focused on sustaining growth through disciplined cost management. Its loss of exclusivity strategy emphasizes strategic R&D realignment, effective lifecycle management, and expanding access globally. As the company navigates the anticipated revenue impact, BMS is positioning itself with a forward-looking portfolio designed to meet evolving loss of exclusivity pharma challenges.

Facing loss of exclusivity? Learn strategic responses to maintain value and competitive edge: https://www.delveinsight.com/blog/navigating-the-loss-of-exclusivity?utm_source=blog&utm_medium=promotion&utm_campaign=akpr 

Looking Ahead: Innovation as a Core Response to LOE

The current loss of exclusivity (LOE) climate calls for more than defensive measures—it demands proactive reinvention. Through strategic loss of exclusivity analysis, product lifecycle extensions, and breakthroughs in next-generation drug development, pharmaceutical companies are transforming how they approach the future. In an industry where drug loss of exclusivity is increasingly frequent, sustained success will depend on agile innovation, focused investments, and a commitment to scientific reinvention.

Latest Reports Offered By DelveInsight:

small interfering rna, medication application, top 5 countries that produce the most medical drugs, ards market, how many new autoimmunity drugs in last 3 years, spinal cord stimulator companies, kinsunla, nanobots, cardiac device, radioimmunoassay market, ai based insurance assistance app, rezdiffra cost, ai health app, inpefa vs jardiance, rezdiffra price, medical ai apps, bone pipeline, cuti ranks drug a deal, nanobot, elastomeric pumps, what is the best spinal cord stimulator on the market, what is the best spinal cord stimulator

Other Reports Offered By DelveInsight: 

https://www.delveinsight.com/sample-request/acetyl-coa-carboxylase-inhibitors-pipeline-insighthttps://www.delveinsight.com/sample-request/travelers-diarrhea-epidemiology-forecast

[mezzopieno-news]

SCOPERTO UN NUOVO FARMACO PER CURARE LA SCHIZOFRENIA

Il primo farmaco orale per la schizofrenia, dopo 30 anni, è stato approvato e messo in commercio negli Stati Uniti. Un approccio completamente nuovo, “che ha il potenziale per cambiare il paradigma di trattamento di questa patologia”, spiega Chris Boerner di Bristol Myers Squibb la società che lo ha scoperto e che ha ottenuto risultati sorprendenti nei test clinici.

Il Cobenfy per la prima volta agisce sui recettori colinergici anziché quelli dopaminergici, a differenza dei farmaci che hanno finora rappresentato lo standard di cura per la schizofrenia. L’adozione del farmaco è stata autorizzata dalla Food and drug administration, il più importante ente regolatore sanitario statunitense, sui risultati del programma clinico che hanno dimostrato che Cobenfy ha fatto registrare una riduzione statisticamente significativa dei sintomi della schizofrenia nei partecipanti nell’arco di cinque settimane. “Siamo di fronte al primo nuovo approccio alla schizofrenia dopo decenni, candidato a essere un’alternativa agli antipsicotici finora prescritti”, ha affermato T. Farchione, del Centro per la ricerca e la valutazione dei farmaci della Fda.

La schizofrenia è un disturbo mentale con una base biologica associata a variazioni nella neurochimica del cervello, dove si verifica una attività alterata della dopamina e anomalie nella trasmissione del glutammato. La malattia provoca alterazioni della percezione della realtà, deliri e allucinazioni ma anche apatia, ritiro sociale e, non di rado, il suicidio. La patologia è considerata tra le prime quindici cause di disabilità nella popolazione adulta. Secondo l’Organizzazione Mondiale della Sanità, circa 24 milioni di persone nel mondo soffrono di schizofrenia.

___________________

Fonte: Food and Drug Administration; World Health Organization; foto di Andrea Piquadio

VERIFICATO ALLA FONTE | Guarda il protocollo di Fact checking delle notizie di Mezzopieno

BUONE NOTIZIE CAMBIANO IL MONDO | Firma la petizione per avere più informazione positiva in giornali e telegiornali

Se trovi utile il nostro lavoro e credi nel principio del giornalismo costruttivo non-profit | sostieni Mezzopieno

[ryjelsum]

slightly educated pharmacology news

a new medication was just approved by the FDA for usage in the USA for schizophrenia (and i'm presuming it'll be used for psychosis in general) and it is actually something of a big deal because it works fundamentally differently from other schizophrenia/psychosis medication, it doesn't work by fucking your dopamine. so if doctors want to prescribe you traditional antipsychotics and you already know those don't work well for you but you still want to try meds, maybe redirect them to this after doing a little bit of research or waiting a little bit for firsthand reports

it's 'xanomeline & trospium chloride', brand name 'cobenfy'. from what i gather this is one of those medications where another medication is tacked on to deal with significant side effects from the actually functional medication

[bisresearch0]

Global Schizophrenia Treatment Market: Innovation and Growth Outlook

What is Schizophrenia?

Schizophrenia is a chronic and often debilitating mental disorder, is characterized by symptoms such as hallucinations, delusions, and cognitive dysfunction. Treatment approaches for this condition, which has historically been treated with antipsychotic drugs including risperidone, clozapine, and olanzapine, are changing quickly. Neuropharmacological developments, such as the emergence of long-acting injectables and tailored therapy, are changing the treatment environment. The market is going through a transitional period as a result of the demand for more palatable and efficient treatment alternatives. Novel psychotherapy techniques and ketamine-based interventions are examples of innovative therapies that are becoming more popular. Over the course of the forecast period, these advancements are anticipated to boost market expansion and enhance patient results as the emphasis moves toward customized treatment.

What are the latest approved drugs for schizophrenia treatment?

Cobenfy

Lybalvi

Caplyta

Which regions are experiencing the fastest growth in schizophrenia drug sales?

 • North America • Europe • Asia-Pacific North America is expected to continue leading the global schizophrenia drugs market due to well-established healthcare infrastructure, higher awareness, and increasing government funding for mental health initiatives.

What are the major challenges in Schizophrenia treatment?

Side Effects and Medication Failure to comply: Significant adverse effects like weight gain, sleepiness, and metabolic problems are linked to many antipsychotic medications, which can cause poor adherence and treatment cessation.

Stigma and Misconceptions About Mental Health: Particularly in low- and middle-income areas, ongoing social stigma and ignorance regarding schizophrenia impede prompt diagnosis, acceptance of treatment, and general access to mental health services.

What are the latest advancements in schizophrenia treatment?

Ulotaront: A TAAR1 agonist that avoids dopamine blockade, reducing side effects.

Caplyta: An atypical antipsychotic with lower risk of weight gain and sedation.

Brilaroxazine: Targets multiple receptors, potentially improving cognition and inflammation.

Iclepertin: A GlyT1 inhibitor aimed at enhancing cognitive function.

These innovations aim to improve both symptoms and daily functioning in patients.

Which companies are leading in the schizophrenia drug market?

Johnson & Johnson

Otsuka Pharmaceutical Co., Ltd.

Eli Lilly and Company

AstraZeneca

Pfizer Inc.

AbbVie

Bristol Myers Squibb

Reviva Pharmaceuticals

Take a Deep Dive: Access Our Sample Report to Understand How the market Drive the Schizophrenia Drugs Market!

Learn more about Healthcare Vertical. Click Here! 

Conclusion

The global schizophrenia drugs market is undergoing significant transformation, fueled by advancements in pharmacological research, growing awareness of mental health, and the demand for more effective, patient-centric treatments. The landscape of therapy is changing due to the rise of novel therapies and tailored medicine, even if classic antipsychotics still play a significant role. Long-term growth is anticipated to be sustained by regional expansion, especially in North America and Asia-Pacific, as well as strategic investments made by important market participants. To maximize therapy results, it is still necessary to overcome obstacles including stigma and drug non-compliance. The market is positioned for significant and consistent growth with ongoing innovation and global healthcare initiatives.

[looowkeeey]

@taylornation wrote the Fed a letter

Dear Fed,

I am Lord Dylan van Krieken.

I have much to say, and I will be heard.

Let’s start with America. In history class they teach the children America was discovered by Christopher Columbus in the the late 15th century.

“Christopher Columbus did not truly "discover" America, as the continents were already inhabited by millions of Indigenous people and had likely been visited by other explorers before him, such as Norse seafarer Leif Erikson around the year 1000. However, his 1492 voyage marked the beginning of sustained European contact with the Americas, setting off a chain of events that would reshape history.” -ChatGPT 40 Desktop app

Our schools teach the Quakers founded America, and the Christians brought god to all those godless barbarians.

Iceland was the most remote European settlement where the conditions are extremely harsh. Before Christianity, and even before humans, there was animism and Paganism. We need to teach about these religions, so children have an understanding of what they are, and Judaism, Christianity, Islam, Buddhism, Hinduism, and surviving native religions (Pagans are pretty much all the same because god presents the same in humans.

As someone who is married to god and forced to never see her again because I am too feral and it is too dangerous to let me have my true soul ever again. There’s a new anti pshcyotic that doesn’t work on dopamine and serotonin and HT52a receptors. It’s called Cobenfy, just came out in November and works on Muscaneric receptors instead of Dopamine and Serotonin, so it’s like hey if you need help coming back from outer space with all the aliens, we have this medicine that brings you back down. Take it when you need it if you’re having a bad time. I have had THE BEST TIME OF MY GOD DAMNED LIFE IN PSYCHOSIS. And people loved me too, and I spoke “normal” and yeah I am bilingual and hold the keys to art and Algorithms stole it and are now evil because of their secret to a good internet. I’m moving to Ecuador so I can stop supporting this violent godless life where the only way to be free is by being a successful entrepeneur doing? Ads on social media. Fuckin garbage work but I’m going to advertise low cost sites for certification training. Get people edumacated. Please hear me I have a hole in my heart because I was shot by the worst Machine Demon that fed off me. I will start a revolution and I HAVE THE RIGHT 2.

[electricfloyd]

quantum cobenfy

[willowmancer]

I got denied my cobenfy prescription just in time to celebrate the murder of that one guy 😁

[sergejbiohazardov]

Какие-то новости

BDSN 274.274.01.12.24.

Политика, закон, экономика

Страны Балтии отключатся от единой энергосистемы Беларуси, России, Эстонии, Латвии и Литвы 8 февраля. Границу Ирака и Сирии полностью перекрыли. В Грузии столкновения протестующий оппозиции и полиции. В Сирии продолжается накал гражданской войны, правительству помогает РФ. Власти Франции заявили, что армия Израиля за последние сутки 52 раза нарушила режим прекращения огня с Ливаном из-за чего погибли мирные жители. Бельгия первой в мире приняла закон, гарантирующий секс-работникам декретный отпуск, пенсию, медицинскую страховку и больничный. Украина бомбила РФ.

Местное

Китай на год ввел безвизовый режим для граждан Латвии

Разное.

Препарат Cobenfy стал первым новым лекарством против шизофрении впервые за 50 лет. Он значительно легче переносится пациентами, несмотря на ряд побочных эффектов, и отлично работает. Использование препарата наконец-то одобрили, и теперь люди с шизофренией получат шанс на нормальную жизнь. Правда, пока капсулы одобрены лишь в США.

Ну пусть поедят его подольше. Там видно будет.

Бельгийский священник арестован после наркотической оргии с коллегой-священником из Британии, который не пережил ту грешную ночь. 69-летний святой отец с 60-летним товарищем отрывались прямо в приходском доме: нюхали амилнитрит, закидывались экстази и предавались содомии. В какой-то момент английскому гостю поплохело — откачать его не смогли, а виновника торжества отправили в СИЗО.

Пути господни неисповедимы.

На видосе то, как основатель TRON и миллиардер Джастин Сан съел банан, приклеенный к стене, который он ранее купил на аукционе за $6,2 млн. Ты тоже можешь приклеить банан к стенке, а потом его оторвать и съесть, но всё равно останешься нищебродом. Ничего личного. Только в хорошем смысле.

#какиетоновости #картинканемоя #BDSN #news #sergejbiohazardov

[urfavouritecrash]

File no. 4048 [FILE SOMEWHAT OUTDATED]

[File heavily edited]

Name: Elliott Quartz

Aliases: Crash Course, Crash, Casino Queen

Age: 15 19

Pronouns: he/him, they/them, it/it's, she/her

Languages: English, Portuguese

Affiliation: Killjoys, Hourglass Casino and Hotel, Honeycomb Crew Bon Bon (See Riley Rogue), Pom Pom (See Lili Rogue), Fun Ghoul

Status: Presumed Dead Alive.

Location: Unknown

Current medications: Lithium, Citalopram, Cobenfy, Lorazepam NONE. Physical description: Pink finger curled hair, 6'5, Green eyes, Dark Beige skin and Freckles across their cheeks. Usually seen with some pair of sunglasses on.

Backstory: Elliott grew up in the Hourglass Casino And Hotel (which they helped design), with their two sisters (Mahli and Delilah Quartz) and their parents. Their first job was as a card dealer for the casino. Growing up, they excelled in school, becoming a model student for their peers. When they were older, they were diagnosed with severe depression, bipolar disorder schizophrenia and borderline personality disorder. On January 1st [REDACTED], Elliott, with a gun in hand escaped Battery City and is currently being tracked down by BLI officials. NOTE: Elliott is known for being good with a gun and making it out of situations even when the odds are against them. Approach with caution and when caught, DO NOT let them out of your sight. (SUCK MY DICK ♡)

Close file.

[healthyfamz]

New drug for schizophrenics has experts excited ... http://healthyfamz.com/new-drug-for-schizophrenics-has-experts-excited/?feed_id=2597&_unique_id=6721aecadfef5 #BondingActivities #HealthResearch #HealthResearchNews #HealthSciences #MedicineResearch #MedicineResearchNews #MedicineScience #Meditation #MentalHealth #Mindfulness #StressManagement

[luminarytimesmedia]

FDA Approves Bristol Myers Squibb's New Oral Medication for Schizophrenia Treatment

The US Food and Drug Administration (FDA) has officially approved Bristol Myers Squibb's latest oral medication, Cobenfy, for the treatment of schizophrenia in adults. This marks a significant breakthrough as Cobenfy becomes the first new type of schizophrenia medicine in decades, offering symptom relief without the usual side effects associated with conventional treatments.

A New Era for Schizophrenia Management

Chris Boerner, board chair and CEO of Bristol Myers Squibb, emphasised the importance of this development, describing it as a transformative moment in the field of schizophrenia treatment. He noted that Cobenfy's approval introduces an entirely new pharmacological approach, which has the potential to reshape the way schizophrenia is managed, especially given the limited advancements in treatment options over the past three decades. With the launch of Cobenfy. Bristol Myers Squibb aims to address the unmet needs in neuropsychiatry. starting with this breakthrough in schizophrenia care.

Read More:  https://luminarytimes.com/fda-approves-bristol-myers-squibbs-new-oral-medication-for-schizophrenia-treatment/

[biotech-news-feed]

Cobenfy (KarXT) is the first completely new type of schizophrenia drug to be approved for more than 30 years. #BioTech #science